



Robert Greene Sterne
Edward J. Kessler
Jorge A. Goldstein
David K.S. Cornwell
Robert W. Edmund
Troy-Gene G. D. Kohn
Michael A. Combs
Michael B. Ilavsky
Robert E. Schmitt
Eric K. Stoff
Michael Q. Lee
Steven R. Ludwig
John M. Corbett
Linda E. Alcorn
Robert C. Manning
Donald J. Featherstone
Lawrence B. Bugalsky
Michael V. Messinger
Judith U. Kim

Timothy J. Shea, Jr.
Patrick E. Garrett
Jeffrey T. Helvey
Hed L. Kraus
Albert L. Ferro
Donald R. Barakat
Peter A. Jackson
Teresa G. Weaver
Jeffrey S. Weaver
Randall P. Patterson
Vincent L. Caputo
Eldora E. son Floyd
Thomas C. Fife
Brian J. Del Buono
Viggo Leo Beaman
Theodore A. Wood
Elizabeth J. Haines
Joseph S. Ostroff
Frank R. Cottingham

Christine M. Uhaler
Rita Lynn P. Gust
George S. Berdmasser
Daniel A. Kahn
Jason D. Eisenberg
Michael D. Speddi
Andrea J. Kammer
Terry L. Meyer
Jan E. Wright
LuAnne M. DeSantis
Ann E. Summerfield
Anne W. Ledford
Helena C. Carlson
Cynthia M. Boudhaz
Timothy A. Doyle
Gabry L. Lengswarth
Lori A. Gordon
Nicole D. Draper
Ted J. Ebersole

John C. Hay
Linda A. Vogel
Michael J. Mancuso
Bryan S. Wade
Adam L. Schwartz
Matthew E. Kiley
Nicole R. Kramer
Registered Patent Agents
Robert R. Makin
Nancy J. Lash
Matthew J. David
Andrew L. Schwartz
Kathleen M. Per Quash
Bryan L. Seaton
Robert A. Schwartzman
Teresa A. Golea
Jeffrey S. Lundgren
Victoria S. Rutherford

Michelle K. Koloszek
Simon J. E. Ott
Julia A. Holder
Mia M. Kozak
Scott M. Woodhouse
Michael G. Penn
Christopher J. Walsh
Peter A. Socrates

Of Counsel
Kenneth C. Bass III
Evan R. Smith
Marvin C. Goshole

*Admitted only in Maryland
*Admitted only in Virginia
*Practice Limited to
Federal Agencies

January 27, 2005

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Re: U.S. Utility Patent Application
Appl. No. 10/801,951; Filed: March 17, 2004
For: **Facially Amphiphilic Polymers and Oligomers and Uses Thereof**
Inventors: DeGRADO *et al.*
Our Ref: 1694.0630003/JMC/AES

Sir:

Applicants submit the following documents for appropriate action by the U.S. Patent and Trademark Office:

1. Information Disclosure Statement;
2. Two (2) pages of Form PTO/SB/08A and eight (8) pages of Form PTO/SB/08B citing ninety-three (93) documents;
3. Copies of seventy-seven (77) cited documents; and
4. One (1) return postcard.

It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036. If extensions of time under 37 C.F.R. § 1.136 other than those otherwise provided for herewith are required to prevent

Commissioner for Patents
January 27, 2005
Page 2

abandonment of the present patent application, then such extensions of time are hereby petitioned, and any fees therefor are hereby authorized to be charged to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Ann E. Summerfield
Attorney for Applicants
Registration No. 47,982

AES/law
Enclosures

358055v1



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

DeGrado *et al.*

Appl. No.: 10/801,951

Filed: March 17, 2004

For: **Facially Amphiphilic Polymers
and Oligomers and Uses Thereof**

Confirmation No.: 2895

Art Unit: 1615

Examiner: *To be assigned*

Atty. Docket: 1694.0630003/JMC/AES

Information Disclosure Statement

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450
Sir:

Listed on accompanying Forms PTO/SB/08A (2 pages) and PTO/SB/08B (8 pages) are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98.

Copies of documents **AA1-AO1** are not provided in accordance with the Changes To Support Implementation of the United States Patent and Trademark Office 21st Century Strategic Plan, effective October 21, 2004, which states "section 1.98(a)(2)(i) is amended to eliminate the requirement in paragraph (a)(2)(i) for a copy of each U.S. patent or U.S. patent application publication listed in an IDS in a patent application regardless of the filing date of the application."

A copy of document **BA8** is not provided in accordance with the U.S. Patent and Trademark Office OG notice of October 19, 2004, which states: "the requirement in 37 C.F.R. § 1.98(a)(2)(iii) for a legible copy of the specification, including the claims, and drawings of each cited pending U.S. patent application (or portion of the application which caused it to be listed) is *sua sponte* waived where the cited pending application is stored in the USPTO's IFW system."

A copy of each other document is provided.

The Examiner's attention is directed to the following co-pending U.S. Patent Applications, which are directed to related technical subject matter:

U.S. Patent Application No. 10/459,698, Lopez *et al.*, filed June 12, 2003, now U.S. Patent Application Publication No. 2004/0102941, cited herewith as document **AL1**;

U.S. Patent Application No. 10/ 446,171, Doerksen *et al.*, filed May 28, 2003, now U.S. Patent Application Publication No. 2004/0107056, cited herewith as document **AM1**;

U.S. Patent Application No. 10/471,028, DeGrado *et al.*, filed September 8, 2003, now U.S. Patent Application Publication No. 2004/0185257, cited herewith as document **AN1**;

U.S. Patent Application No. 10/471,029, DeGrado *et al.*, filed September 8, 2003, now U.S. Patent Application Publication No. 2004/0202639, cited herewith as document **AO1**; and

U.S. Patent Application entitled "Facially Amphiphilic Polyaryl and Polyarylkynyl Polymers and Oligomers and Uses Thereof," filed January 21, 2005, naming as inventors William F. DeGrado, Dahui Liu, Gregory N. Tew, and Michael L. Klein (Attorney Docket No. 1694.0590001/JMC/AES), cited herewith as document **BA8**.

The identification of these U.S. Patent Applications is not to be construed as a waiver of secrecy as to these applications now or upon issuance of the present application as a patent. The Examiner is respectfully requested to consider the cited applications and the art cited therein during examination.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached Forms PTO/SB/08A and PTO/SB/08B based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

DeGrado *et al.*
Appl. No. 10/801,951

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith.

This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits. No statement or fee is required.

It is respectfully requested that the Examiner initial and return a copy of the enclosed Forms PTO/SB/08A and PTO/SB/08B, and indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Ann E. Summerfield
Attorney for Applicants
Registration No. 47,982

Date: January 27, 2005
1100 New York Avenue, N.W.
Washington, D.C. 20005-3934
(202) 371-2600
334527 1.DOC



PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Project of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/801,951
				Filing Date	March 17, 2004
				First Named Inventor	William F. DeGrado
				Art Unit	1615
				Examiner Name	To be assigned
				Attorney Docket Number	1694.0630003/JMC/AES
Sheet	1	of	2		

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	AA1	3,829,563	08/13/1974	Barry <i>et al.</i>	
	AB1	4,343,788	08/10/1982	Mustacich <i>et al.</i>	
	AC1	4,392,848	07/12/1983	Lucas <i>et al.</i>	
	AD1	5,071,648	12/10/1991	Rosenblatt	
	AE1	5,847,047	12/08/1998	Haynie	
	AF1	5,856,245	01/05/1999	Caldwell <i>et al.</i>	
	AG1	5,874,164	02/23/1999	Caldwell	
	AH1	5,912,116	06/15/1999	Caldwell	
	AI1	6,034,129	03/07/2000	Mandeville III <i>et al.</i>	
	AJ1	6,040,251	03/21/2000	Caldwell	
	AK1	6,083,602	07/04/2000	Caldwell <i>et al.</i>	
	AL1	2004/0102941	05/27/2004	Lopez <i>et al.</i>	
	AM1	2004/0107056	06/03/2004	Doerksen <i>et al.</i>	
	AN1	2004/0185257	09/23/2004	DeGrado <i>et al.</i>	
	AO1	2004/0202639	10/14/2004	DeGrado <i>et al.</i>	
	AP				
	AQ				
	AR				
	AS				

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, columns, lines, where relevant passages or figures appear	T ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				
	AT1	WO 90/04401	05/03/1990	Lehigh University		
	AU1	WO 95/00547	01/05/1995	E.I. DuPont De Nemours & Co.		
	AV1	WO 97/29160	08/14/1997	Surface Solutions Labs., Inc.		
	AW1	WO 97/49413	12/31/1997	Geltex Pharmaceuticals, Inc.		
	AX1	WO 02/072007	09/19/2002	The Univ. of Pennsylvania		
	AY1	WO 02/100295	12/19/2002	The Univ. of Pennsylvania		

334136_1.DOC

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbol as indicated on the document under WIPO Standard ST 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/801,951
				Filing Date	March 17, 2004
				First Named Inventor	William F. DeGrado
				Art Unit	1615
				Examiner Name	To be assigned
Sheet	2	of	2	Attorney Docket Number	1694.0630003/JMC/AES

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	AA				
	AB				
	AC				
	AD				
	AE				
	AF				
	AG				
	AH				
	AI				
	AJ				
	AK				
	AL				
	AM				
	AN				
	AO				
	AP				
	AQ				
	AR				
	AS				

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				
	AT2	WO 04/082634	09/30/2004	DeGrado <i>et al.</i>		
	AU					
	AV					
	AW					
	AX					
	AY					

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/801,951
				Filing Date	March 17, 2004
				First Named Inventor	William F. DeGrado
				Art Unit	1615
				Examiner Name	To be assigned
Sheet	1	of	8	Attorney Docket Number	1694.0630003/JMC/AES

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author, title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published, etc.	T ²
	BA1	Andersen, J.H., <i>et al.</i> , "Lactoferrin and cyclic lactoferricin inhibit the entry of human cytomegalovirus into human fibroblasts," <i>Antiviral Res.</i> 51:141-149, Elsevier (2001)	
	BB1	Barany, G., <i>et al.</i> , "Solid-phase peptide synthesis: a silver anniversary report," <i>Int. J. Pept. Protein Res.</i> 30:705-739, Munksgaard International Publishers (1987)	
	BC1	Barron, A.E., and Zuckerman, R.N., "Bioinspired polymeric materials: in-between proteins and plastics," <i>Curr. Opin. Chem. Biol.</i> 3:681-687, Current Biology Ltd. (1999)	
	BD1	Bastian, A., and Schäfer, H., "Human α -defensin 1 (HNP-1) inhibits adenoviral infection in vitro," <i>Regul. Pept.</i> 101:157-161, Elsevier (2001)	
	BE1	Belaid, A., <i>et al.</i> , "In Vitro Antiviral Activity of Dermaseptins Against Herpes Simplex Virus Type 1," <i>J. Med. Virol.</i> 66:229-234, Wiley-Liss (February 2002)	
	BF1	Bjørnholm, T., <i>et al.</i> , "Self-Assembly of Regioregular, Amphiphilic Polythiophenes into Highly Ordered π -Stacked Conjugated Polymer Thin Films and Nanocircuits," <i>J. Am. Chem. Soc.</i> 120:7643-7644, American Chemical Society (1998)	
	BG1	Boman, H.G., "Innate immunity and the normal microflora," <i>Immunol. Rev.</i> 173:5-16, Munksgaard International Publishers (2000)	
	BH1	Boman, H.G., <i>et al.</i> , "Cell-free immunity in Cecropia. A model system for antibacterial proteins," <i>Eur. J. Biochem.</i> 201:23-31, Blackwell Science Ltd. (1991)	
	BI1	Bradley, J.S., and Scheld, W.M., "The Challenge of Penicillin-Resistant <i>Streptococcus pneumoniae</i> Meningitis: Current Antibiotic Therapy in the 1990s," <i>Clin. Infect. Dis.</i> 24 (Suppl. 2):S213-221, University of Chicago Press (1997)	
	BJ1	Broekaert, W.F., <i>et al.</i> , "An automated quantitative assay for fungal growth inhibition," <i>FEMS Microbiol. Lett.</i> 69:55-60, Elsevier (1990)	

334148_1.DOC

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.93. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/801,951
				Filing Date	March 17, 2004
				First Named Inventor	William F. DeGrado
				Art Unit	1615
Examiner Name	To be assigned				
Sheet	2	of	8	Attorney Docket Number	1694.0630003/JMC/AES

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author, title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published, etc.	T ²
	BA2	Butler, J.C., <i>et al.</i> , "The Continued Emergence of Drug-Resistant <i>Streptococcus pneumoniae</i> in the United States: An Update from the Centers for Disease Control and Prevention's Pneumococcal Sentinel Surveillance System," <i>J. Infect. Dis.</i> 174:986-993, University of Chicago Press (1996)	
	BB2	Chen, J., <i>et al.</i> , "Development of Protegrins for the Treatment and Prevention of Oral Mucositis: Structure-Activity Relationships of Synthetic Protegrin Analogues," <i>Biopolymers</i> 55:88-98, Wiley Interscience (2000)	
	BC2	Cole, A.M., <i>et al.</i> , "Retrocyclin: A primate peptide that protects cells from infection by T- and M-tropic strains of HIV-1," <i>Proc. Natl. Acad. Sci USA</i> 99:1813-1818, National Academy of Sciences (February 2002)	
	BD2	Debono, M., and Gordee, R.S., "Antibiotics that Inhibit Fungal Cell Wall Development," <i>Annu. Rev. Microbiol.</i> 48:471-497, Annual Reviews (1994)	
	BE2	DeGrado, W.F., "Design of Peptides and Proteins," in <i>Advances in Protein Chemistry, Volume 39</i> , Anfinsen, C.B., <i>et al.</i> , eds., Academic Press, Inc., San Diego, CA, pp. 51-124 (1988)	
	BF2	DeGrado, W.F., <i>et al.</i> , "Design, Synthesis, and Characterization of a Cytotoxic Peptide with Melittin-Like Activity," <i>J. Amer. Chem. Soc.</i> 103:679-681, American Chemical Society (1981)	
	BG2	DeGrado, W.F., <i>et al.</i> , "Kinetics and Mechanism of Hemolysis Induced by Melittin and by a Synthetic Melittin Analogue," <i>Biophys. J.</i> 37:329-338, Rockefeller University Press (1982)	
	BH2	DeLucca, A.J., and Walsh, T.J., "Antifungal Peptides: Novel Therapeutic Compounds against Emerging Pathogens," <i>Antimicrob. Agents Chemother.</i> 43:1-11, American Society for Microbiology (1999)	
	BI2	Dempsey, C.E., "The actions of melittin on membranes," <i>Biochim. Biophys. Acta</i> 1031:143-161, Elsevier (1990)	
	BJ2	Diness, V., and Østergaard, P.B., "Neutralization of a Low Molecular Weight Heparin (LHN-1) and Conventional Heparin by Protamine Sulfate in Rats," <i>Thromb. Haemost.</i> 56:318-322, Schattauer (1986)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional) ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/801,951
				Filing Date	March 17, 2004
				First Named Inventor	William F. DeGrado
				Art Unit	1615
				Examiner Name	To be assigned
Sheet	3	of	8	Attorney Docket Number	1694.0630003/JMC/AES

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author, title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published, etc.	T ²
	BA3	Edwards, J.R., <i>et al.</i> , "In Vitro Antibacterial Activity of SM-7338, a Carbapenem Antibiotic with Stability to Dehydropeptidase I," <i>Antimicrob. Agents Chemother.</i> 33:215-222, American Society for Microbiology (1989)	
	BB3	Egal, M., <i>et al.</i> , "Antiviral effects of synthetic membrane-active peptides on Herpes Simplex Virus, Type 1," <i>Int. J. Antimicrob. Agents</i> 13:57-60, Elsevier (1999)	
	BC3	Ganz, T., <i>et al.</i> , "Defensins," <i>Eur. J. Haematol.</i> 44:1-8, Munksgaard (1990)	
	BD3	Ganz, T., <i>et al.</i> , "Defensins. Natural Peptide Antibiotics of Human Neutrophils," <i>J. Clin. Invest.</i> 76:1427-1435, American Society for Clinical Investigation (1985)	
	BE3	Gazit, E., <i>et al.</i> , "Interaction of the Mammalian Antibacterial Peptide Cecropin P1 with Phospholipid Vesicles," <i>Biochemistry</i> 34:11479-11488, American Chemical Society (1995)	
	BF3	Gellman, S.H., "Foldamers: A Manifesto," <i>Acc. Chem. Res.</i> 31:173-180, American Chemical Society (1998)	
	BG3	Gennaro, R., and Zanetti, M., "Structural Features and Biological Activities of the Cathelicidin-Derived Antimicrobial Peptides," <i>Biopolymers</i> 55:31-49, Wiley Interscience (2000)	
	BH3	Hamuro, Y., <i>et al.</i> , "De Novo Design of Antibacterial β -Peptides," <i>J. Am. Chem. Soc.</i> 121:12200-12201, American Chemical Society (1999)	
	BI3	Hamuro, Y., <i>et al.</i> , "Novel Folding Patterns in a Family of Oligoanthranilamides: Non-Peptide Oligomers That Form Extended Helical Secondary Structures," <i>J. Am. Chem. Soc.</i> 119:10587-10593, American Chemical Society (1997)	
	BJ3	Hancock, R.E.W., and Lehrer, R., "Cationic peptides: a new source of antibiotics," <i>Trends Biotechnol.</i> 16:82-88, Elsevier Science Publishers B.V. (1998)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/801,951
				Filing Date	March 17, 2004
				First Named Inventor	William F. DeGrado
				Art Unit	1615
				Examiner Name	To be assigned
Sheet	4	of	8	Attorney Docket Number	1694.0630003/JMC/AES

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author, title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published, etc.	T ²
	BA4	Haynie, S.L., <i>et al.</i> , "Antimicrobial Activities of Amphiphilic Peptides Covalently Bonded to a Water-Insoluble Resin," <i>Antimicrob. Agents Chemother.</i> 39:301-307, American Society For Microbiology (1995)	
	BB4	Hiramatsu, K., <i>et al.</i> , "Methicillin-resistant <i>Staphylococcus aureus</i> clinical strain with reduced vancomycin susceptibility," <i>J. Antimicrob. Chemother.</i> 40:135-136, Oxford University Press (1997)	
	BC4	Hirsh, J., and Levine, M.N., "Low Molecular Weight Heparin," <i>Blood</i> 79:1-17, American Society of Hematology (1992)	
	BD4	Javadpour, M.M., <i>et al.</i> , "De Novo Antimicrobial Peptides with Low Mammalian Cell Toxicity," <i>J. Med. Chem.</i> 39:3107-3113, American Chemical Society (1996)	
	BE4	Kandrotas, R.J., "Heparin Pharmacokinetics and Pharmacodynamics," <i>Clin. Pharmacokinet.</i> 22:359-374, Adis International Ltd. (1992)	
	BF4	Landon, C., <i>et al.</i> , "Solution structure of drosomycin, the first inducible antifungal protein from insects," <i>Protein Sci.</i> 6:1878-1884, Cambridge University Press (1997)	
	BG4	Liu, D. <i>et al.</i> , "Nontoxic Membrane-Active Antimicrobial Arylamide Oligomers," <i>Angew. Chem. Int. Ed. Engl.</i> 43:1158-1162, Verlag Chemie (February 2004)	
	BH4	Liu, D., and DeGrado, W.F., "De Novo Design, Synthesis, and Characterization of Antimicrobial β -Peptides," <i>J. Amer. Chem. Soc.</i> 123:7553-7559, American Chemical Society (2001)	
	BI4	Lyytikäinen, O., <i>et al.</i> , "Outbreak caused by two multi-resistant <i>Acinetobacter baumannii</i> clones in a burns unit: emergence of resistance to imipenem," <i>J. Hosp. Infect.</i> 31:41-54, W.B. Saunders (1995)	
	BJ4	Maloy, W.L., and Kari, U.P., "Structure-Activity Studies on Magainins and Other Host Defense Peptides," <i>Biopolymers</i> 37:105-122, Wiley (1995)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449-PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/801,951
				Filing Date	March 17, 2004
				First Named Inventor	William F. DeGrado
				Art Unit	1615
Examiner Name	To be assigned				
Sheet	5	of	8	Attorney Docket Number	1694.0630003/JMC/AES

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author, title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published, etc.	T ²
	BA5	Margel, S., <i>et al.</i> , "Peptide, protein, and cellular interactions with self-assembled monolayer model surfaces," <i>J. Biomed. Mater. Res.</i> 27:1463-1476, Wiley Interscience (1993)	
	BB5	Merrifield, E.L., <i>et al.</i> , "D-Enantiomers of 15-residue cecropin A-melittin hybrids," <i>Int. J. Pept. Protein Res.</i> 46:214-220, Munksgaard International Publishers (1995)	
	BC5	Merrifield, R.B., <i>et al.</i> , "Design and synthesis of antimicrobial peptides," <i>Ciba Found. Symp.</i> 186:5-26, Wiley (1994)	
	BD5	Merrifield, R.B., <i>et al.</i> , "Retro and retroenantio analogs of cecropin-melittin hybrids," <i>Proc. Natl. Acad. Sci. USA</i> 92:3449-3453, National Academy of Sciences (1995)	
	BE5	Montecalvo, M.A., <i>et al.</i> , "Outbreak of Vancomycin-, Ampicillin-, and Aminoglycoside-Resistant <i>Enterococcus faecium</i> Bacteremia in an Adult Oncology Unit," <i>Antimicro. Agents Chemother.</i> 38:1363-1367, American Society for Microbiology (1994)	
	BF5	Oren, Z., and Shai, Y., "Mode of Action of Linear Amphipathic α -Helical Antimicrobial Peptides," <i>Biopolymers</i> 47:451-463, Wiley Interscience (1998)	
	BG5	Peggion, E., <i>et al.</i> , "Conformation and Interactions of Bioactive Peptides from Insect Venoms: The Bombolitins," <i>Biopolymers</i> 43:419-431, Wiley Interscience (1997)	
	BH5	Porter, E.A., <i>et al.</i> , "Antibiotics: Non-haemolytic β -amino-acid oligomers," <i>Nature</i> 404:565, Nature Publishing Group (2000)	
	BI5	Pouny, Y., <i>et al.</i> , "Interaction of Antimicrobial Dermaseptin and Its Fluorescently Labeled Analogs with Phospholipid Membranes," <i>Biochemistry</i> 31:12416-12423, American Chemical Society (1992)	
	BJ5	Samson, N., <i>et al.</i> , "Relationships Between Synthesis and Mechanical Properties of New Polyurea Materials," <i>J. Appl. Polym. Sci.</i> 65:2265-2280, Wiley (1997)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/801,951
				Filing Date	March 17, 2004
				First Named Inventor	William F. DeGrado
				Art Unit	1615
				Examiner Name	To be assigned
Sheet	6	of	8	Attorney Docket Number	1694.0630003/JMC/AES

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author, title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published, etc.	T ²
	BA6	Sinha, S., <i>et al.</i> , "NP-1, a Rabbit α -Defensin, Prevents the Entry and Intercellular Spread of Herpes Simplex Virus Type 2," <i>Antimicrob. Agents Chemother.</i> 47:494-500, American Society for Microbiology (February 2003)	
	BB6	Steiner, H., <i>et al.</i> , "Sequence and specificity of two antibacterial proteins involved in insect immunity," <i>Nature</i> 292:246-248, Nature Publishing Group (1981)	
	BC6	Stigers, K.D., <i>et al.</i> , "Designed molecules that fold to mimic protein secondary structures," <i>Curr. Opin. Chem. Biol.</i> 3:714-723, Current Biology Ltd. (1999)	
	BD6	Tang, Y-Q., <i>et al.</i> , "A Cyclic Antimicrobial Peptide Produced in Primate Leukocytes by the Ligation of Two Truncated α -Defensins," <i>Science</i> 286:498-502, American Association for the Advancement of Science (1999)	
	BE6	Tew, G.N., <i>et al.</i> , "De novo design of biomimetic antimicrobial polymers," <i>Proc. Natl. Acad. Sci. USA</i> 99:5110-5114, National Academy of Sciences (April 2002)	
	BF6	Threlfall, E.J., <i>et al.</i> , "Increasing spectrum of resistance in multiresistant <i>Salmonella typhimurium</i> ," <i>Lancet</i> 347:1053-1054, Lancet Publishing Group (1996)	
	BG6	Tiller, J.C., <i>et al.</i> , "Designing surfaces that kill bacteria on contact," <i>Proc. Natl. Acad. Sci. USA</i> 98:5981-5985, National Academy of Sciences (2001)	
	BH6	Tossi, A., <i>et al.</i> , "Amphipathic, α -Helical Antimicrobial Peptides," <i>Biopolymers</i> 55:4-30, Wiley Interscience (2000)	
	BI6	Turpie, A.G.G., "Pharmacology of the low-molecular-weight heparins," <i>Am. Heart J.</i> 135:S329-S335, Mosby (1998)	
	BJ6	Van Ryn-McKenna, J., <i>et al.</i> , "Neutralization of Enoxaparine-Induced Bleeding by Protamine Sulfate," <i>Thromb. Haemost.</i> 63:271-274, Schattauer (1990)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/801,951
				Filing Date	March 17, 2004
				First Named Inventor	William F. DeGrado
				Art Unit	1615
				Examiner Name	To be assigned
Sheet	7	of	8	Attorney Docket Number	1694.0630003/JMC/AES

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author, title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published, etc.	T ²
	BA7	Wachinger, M., <i>et al.</i> , "Antimicrobial peptides melittin and cecropin inhibit replication of human immunodeficiency virus 1 by suppressing viral gene expression," <i>J. Gen. Virol.</i> 79:731-740, Cambridge University Press (1998)	
	BB7	Wakefield, T.W., <i>et al.</i> , "A [+18RGD] Protamine Variant for Nontoxic and Effective Reversal of Conventional Heparin and Low-Molecular-Weight Heparin Anticoagulation," <i>J. Surg. Res.</i> 63:280-286, Academic Press (1996)	
	BC7	Wong, P.C., <i>et al.</i> , "Nonpeptide Factor Xa Inhibitors: I. Studies with SF303 and SK549, a New Class of Potent Antithrombotics," <i>J. Pharmacol. Exp. Therap.</i> 292:351-357, American Society for Pharmacology and Experimental Therapeutics (2000)	
	BD7	Woo, G.L.Y., <i>et al.</i> , "Synthesis and characterization of a novel biodegradable antimicrobial polymer," <i>Biomaterials</i> 21:1235-1246, Elsevier (2000)	
	BE7	Yamaguchi, I., <i>et al.</i> , "Synthesis of polyurea rotaxanes using a cyclodextrin complex of α,ω -diamine," <i>Polym. Bull.</i> 44:247-253, Springer-Verlag (2000)	
	BF7	Zasloff, M., "Antibiotic peptides as mediators of innate immunity," <i>Curr. Opin. Immunol.</i> 4:3-7, Current Biology Ltd. (1992)	
	BG7	Zasloff, M., "Antimicrobial peptides of multicellular organisms," <i>Nature</i> 415:389-395, Nature Publishing Group (January 2002)	
	BH7	Zasloff, M., "Reconstructing one of nature's designs," <i>Trends Pharmacol. Sci.</i> 21:236-238, Elsevier (2000)	
	BI7	Zhang, L., <i>et al.</i> , "Contribution of Human α -Defensin 1, 2, and 3 to the Anti-HIV-1 Activity of CD8 Antiviral Factor," <i>Science</i> 298:995-1000, American Association for the Advancement of Science (November 2002)	
	BJ7	Zhao, C., <i>et al.</i> , "Identification of a new member of the protegrin family by cDNA cloning," <i>FEBS Lett.</i> 346:285-288, Elsevier (1994)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.93. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/801,951
				Filing Date	March 17, 2004
				First Named Inventor	William F. DeGrado
				Art Unit	1615
				Examiner Name	To be assigned
Sheet	8	of	8	Attorney Docket Number	1694.0630003/JMC/AES

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author, title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published, etc.	T ²
	BA8	U.S. Patent Application entitled "Facially Amphiphilic Polyaryl and Polyaryllalkynyl Polymers and Oligomers and Uses Thereof," filed January 21, 2005, naming as inventors William F. DeGrado, Dahui Liu, Gregory N. Tew, and Michael L. Klein, (Attorney Docket No. 1694.0590001/JMC/AES)	
	BB		
	BC		
	BD		
	BE		
	BF		
	BG		
	BH		
	BI		
	BJ		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.